Anti-HIPL2/ HHIPL2/ KIAA1822L functional antibody
Anti-HIPL2/ HHIPL2/ KIAA1822L functional antibody for cell culture, ELISA & in-vivo assay
Go to HHIPL2/HHIPL2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-SE0262-Ab-1/ GM-Tg-hg-SE0262-Ab-2 | Anti-Human HHIPL2 monoclonal antibody | Human |
GM-Tg-rg-SE0262-Ab-1/ GM-Tg-rg-SE0262-Ab-2 | Anti-Rat HHIPL2 monoclonal antibody | Rat |
GM-Tg-mg-SE0262-Ab-1/ GM-Tg-mg-SE0262-Ab-2 | Anti-Mouse HHIPL2 monoclonal antibody | Mouse |
GM-Tg-cynog-SE0262-Ab-1/ GM-Tg-cynog-SE0262-Ab-2 | Anti-Cynomolgus/ Rhesus macaque HHIPL2 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-SE0262-Ab-1/ GM-Tg-felg-SE0262-Ab-2 | Anti-Feline HHIPL2 monoclonal antibody | Feline |
GM-Tg-cang-SE0262-Ab-1/ GM-Tg-cang-SE0262-Ab-2 | Anti-Canine HHIPL2 monoclonal antibody | Canine |
GM-Tg-bovg-SE0262-Ab-1/ GM-Tg-bovg-SE0262-Ab-2 | Anti-Bovine HHIPL2 monoclonal antibody | Bovine |
GM-Tg-equg-SE0262-Ab-1/ GM-Tg-equg-SE0262-Ab-2 | Anti-Equine HHIPL2 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-SE0262-Ab-1/ GM-Tg-hg-SE0262-Ab-2; GM-Tg-rg-SE0262-Ab-1/ GM-Tg-rg-SE0262-Ab-2; GM-Tg-mg-SE0262-Ab-1/ GM-Tg-mg-SE0262-Ab-2; GM-Tg-cynog-SE0262-Ab-1/ GM-Tg-cynog-SE0262-Ab-2; GM-Tg-felg-SE0262-Ab-1/ GM-Tg-felg-SE0262-Ab-2; GM-Tg-cang-SE0262-Ab-1/ GM-Tg-cang-SE0262-Ab-2; GM-Tg-bovg-SE0262-Ab-1/ GM-Tg-bovg-SE0262-Ab-2; GM-Tg-equg-SE0262-Ab-1/ GM-Tg-equg-SE0262-Ab-2 |
Products Name | Anti-HHIPL2 monoclonal antibody |
Format | mab |
Target Name | HHIPL2 |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-HHIPL2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-SE0262-Ag-1 | Recombinant multi-species HIPL2/ HHIPL2/ KIAA1822L protein |
Target information
Target ID | GM-SE0262 |
Target Name | HHIPL2 |
Gene ID | 79802,78772,317051,704732,478998,101101029,533766,100055380 |
Gene Symbol and Synonyms | 4930507C10Rik,Hhip3,HHIPL2,KIAA1822L,RGD1311317 |
Uniprot Accession | Q6UWX4 |
Uniprot Entry Name | HIPL2_HUMAN |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000143512 |
Target Classification | N/A |
The target: HHIPL2, gene name: HHIPL2, also named as KIAA1822L. Predicted to enable catalytic activity. Predicted to be located in extracellular region. [provided by Alliance of Genome Resources, Apr 2022].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.